News

The European Medicines Agency has launched a voluntary framework for sharing data from non-animal testing methods to build regulatory confidence and refine drug development.

Novartis has signed a landmark agreement with South Korean biopharmaceutical firm Alteogen, potentially valued at up to $3.22 billion, for the development and commercialisation of subcutaneous drug formulations powered by Alteogen's proprietary ALT-B4 technology. A Multi-Option Agreement Targeting Subcutaneous Formulation The...

Medication safety is not limited to achieving the intended therapeutic effect. In 2024, the US Food and Drug Administration (FDA) published an article titled ‘Some Medicines and Driving Don’t Mix,’ and there is much truth to that. Many prescription medications...

Novo Nordisk has announced a strategic partnership with Amazon Web Services (AWS), naming it its preferred cloud provider and strategic AI partner, with the shared goal of accelerating drug discovery and modernising the company's technology infrastructure to prepare for...

The Trump administration is preparing to announce a new round of voluntary drug-pricing agreements with midsize biotech companies as early as August 31, 2026, according to sources familiar with the matter. The companies involved are expected to offer discounts on...

Huawei intends to deepen its artificial intelligence partnerships with pharmaceutical companies, according to William Zhang, president of the company's healthcare business unit, who confirmed to Reuters that the firm's current AI drug projects run predominantly with domestic Chinese drugmakers....

US-based healthcare services provider McKesson has agreed to acquire Precision Medicine Group for $2.25 billion, a move aimed at strengthening its clinical research and biopharmaceutical commercialisation services. The McKesson acquisition remains subject to customary closing conditions, including regulatory approvals. Once...